The Week

Johnson & Johnson (JNJ) closed the week at $265.58, down 3.51%. The S&P 500 fell 0.8% over the same period, leaving JNJ about 2.71 percentage points below the benchmark. The stock opened Tuesday at $271.28 and hit a weekly high of $271.99 before drifting lower over the next three sessions. Wednesday and Thursday both ended in the red, and Friday touched an intraday low of $265.25 before settling near the bottom of the range. Weekly amplitude was 2.48%, and average daily volume ran about 18.74% below its recent median, a quiet pullback.\n\n## Key Events\n\nMedTech and product approvals framed the week\u2019s story. Early on, commentary asked whether the IMAAVY approval and the ongoing talc verdicts materially changed the bull case for JNJ, though no new court outcome landed during the week. On Tuesday, Johnson & Johnson Innovation named Silvia Chen head of JLABS Shanghai, extending the company\u2019s push into innovation ecosystems. Thursday brought CE Marking for ACUVUE OASYS MAX reusable contact lenses, and JNJ shares moved higher on the news. Cardiovascular was flagged as the central growth theme in high-end MedTech. On Friday, RBC Capital reiterated its buy rating on JNJ. Over the weekend, Bloomberg News reported that Apollo Global is in talks to acquire J&J\u2019s orthopedics unit, while the company also signalled a bet on the Ottava system in robotic surgery. A settlement notice related to Skin360 skin-assessment apps was also published over the weekend.\n\n## Analyst Ratings\n\nThe latest consensus draws on 24 institutions: 11 rate JNJ buy, 5 overweight, 6 hold, 1 sell and 1 no opinion. The consensus rating is buy, with a target price of $277.91, about 4.64% above the $265.58 spot. The target range is wide, from $190 to $320, pointing to meaningful dispersion in medium-term views. JNJ ranks 5th within its pharmaceutical industry group of 206 names.\n\n## The Week Ahead\n\nA batch of US retail and manufacturing data arrives next week: the New York Fed manufacturing index on 15 September, followed by retail sales, retail sales ex-autos, import prices and the NAHB housing market index on 16 September. These prints may shift sentiment around defensive and healthcare names. On the company side, JNJ\u2019s next earnings report is scheduled for 13 October pre-market, with estimates at $2.07 EPS and $25.2bn in revenue. Any follow-through on the orthopedics divestiture talks or the Ottava robotics push would also sit squarely on the radar.\n\n## In Short\n\nJNJ logged a 3.51% weekly decline on light volume and lagged the S&P 500, yet the consensus rating remains buy and the consensus target sits above spot, with JNJ ranked towards the top of its industry. Valuation is not cheap at roughly 30.42x P/E and 7.53x P/B. The latest session\u2019s capital flows showed large-lot money as a net buyer, while small and medium orders were net sellers. The stock sits near the top of its 60-day range at $281.07, leaving a tension between the MedTech growth narrative and asset-sale repricing talk on one side, and this week\u2019s step-down price action on the other. What happens next depends on whether the orthopedics talks and robotics progress deliver new catalysts, and how the coming US data read-through hits defensive positioning.\n\nThis article is generated by LongbridgeAI from market data, for information only and not investment advice.